High Ly6K mRNA expression in lung cancer was significantly correlated with poor five-year relapse free survival with restriction of stage IIb cancer (low Ly6K, n=18; high Ly6K, n=21; HR=2.02, p=0.002); five year overall survival with restriction of stage IIIb cancer (low Ly6K, n=17; high Ly6K, n=18; HR=1.57, p=0.013) and with restriction of stage IIb cancer (low Ly6K, n=18; high Ly6K, n=21; HR=1.98, p=0.002) shown by PROGgeneV2 (Table S4, Figure 4B). The gene discussed is LY6K; the disease is lung carcinoma.